High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS.
نویسندگان
چکیده
INTRODUCTION Recommendations for adjuvant treatment of DCIS after breast conservation are controversial. We tried to identify further risk factors in a retrospective study of our own practice. PATIENTS AND METHODS Three hundred and thirty-two patients treated by breast conservation between 1978 and 2001 at the Department of General Surgery, University of Vienna were analysed. Tumour size, nuclear grade, hormone receptors, p53, her-2/neu, multifocality, microinvasion and post-operative therapy (irradiation, tamoxifen or combination) were analysed for their influence on breast recurrence. RESULTS Overall recurrence rate was 6.1% (8/132). For patients with DCIS showing high nuclear grade or negative estrogen receptor the risk for development of ipsilateral breast recurrence is significantly higher. Newer factors like p53 and her-2/neu do not have any prognostic significance. No recurrence was observed in patients treated by post-operative irradiation and tamoxifen. CONCLUSION Nuclear grade remains the most significant factor for breast recurrence after DCIS. Hormone receptor status identifies a subset of patients with more favourable prognosis.
منابع مشابه
Androgen Receptor Analysis in Relation to Estrogen and Progesterone Receptors as well as Histological Grade for Ductal Carcinoma In Situ of the Breast
Background and Objective: Since the advent of mammography screening, ductal carcinoma in situ (DCIS) of the breast has been diagnosed increasingly. In contrast to the situation in invasive breast carcinoma, there are only a few reports on androgen receptor (AR) status in DCIS and few reports on estrogen ...
متن کاملPredictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis
The introduction of mammographic screening has considerably increased the detection rate of ductal carcinoma in situ (DCIS), which has a high probability of recurrence. We carried out a meta-analysis to evaluate the predictive factors including biomarkers, tumor characteristics, and modes of detection on the risk of local invasive recurrence (LIR) following DCIS. Searches were performed in PubM...
متن کاملAbsence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
The type 1 tyrosine kinase receptor HER2 (c-erbB2/neu) is associated with resistance to hormone therapy and poor survival in invasive breast cancer, whereas HER4 expression is associated with endocrine responsiveness. Patterns of tyrosine kinase receptor coexpression may aid prediction of recurrence risk after surgery for ductal carcinoma in situ (DCIS). Women who had undergone surgery for pure...
متن کاملPredictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery
PURPOSE Local recurrence is a major concern in patients who have undergone surgery for ductal carcinoma in situ (DCIS). The present study assessed whether the expression levels of hormone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67, as well as resection margin status, tumor grade, age at diagnosis, and adjuvant hormonal therapy and radiotherapy (RT) are associated with...
متن کاملAssociation Between Oncotype DX Recurrence Score and Clinicopathological Variables in Breast Cancer Patients
Introduction: Breast cancer is the most common cancer and the leading cause of cancer-related death in women. Clinicopathological variables are important factors in deciding on breast cancer treatment. This study evaluated the association between the recurrence score generated by the Oncotype DX® 21-gene assay and classic clinicopathological variables. Methods: A single-institution retrospect...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
دوره 30 3 شماره
صفحات -
تاریخ انتشار 2004